Table 6. Relapse location and outcome of recurring patients.

Patients	Relapse location	Treatment	Outcome
1	Liver followed by pulmonary and lymph nodes metastases	Segmentectomy, systemic treatment†, followed by supportive care	HCC-related mortality due to rapidly progressive disease
2	Simultaneous liver and bone metastases	Bevacizumab and atezolizumab; radiation therapy in the localized bone metastasis	Complete radiologic response
3	Cardiac metastasis	Systemic treatment‡	Awaiting treatment evaluation
4	Liver	TACI followed by PTA	Awaiting for LT
5	Liver	Sorafenib followed by bevacizumab and atezolizumab	Stable disease
6	Liver	LT	Mortality related to a sudden cardiac arrest
7	Liver	Supportive care	–

^†, Nexavar followed by Lenmiva; ^‡, pembrolizumab due to a synchronous lingual tumor. HCC, hepatocellular carcinoma; TACI, transarterial chemo-infusion; PTA, percutaneous thermal ablation; LT, liver transplantation.